Literature DB >> 25463432

IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion.

Sojan Abraham1, Jang-gi Choi1, Chunting Ye1, N Manjunath1, Premlata Shankar2.   

Abstract

Although patients with GVHD have elevated serum levels of IL10, whether its role is protective or pathogenic remains unclear. Here, we used a humanized mouse model to study the role of IL-10 in GVHD. When human PBMCs were engrafted in NOD-scid IL2rγc(null) mice expressing human IL-10, the T cells underwent massive expansion resulting in lethality by day 21, whereas control mice survived for at least 40 days. Histopathology of the liver showed extensive mononuclear cell infiltration in IL-10 expressing but not in control mice. Corresponding to their aggressiveness, the T cells in the IL-10 group exhibited predominantly an effector memory phenotype (CD45RO(+)CD27(-)) while in control mice, the T cells were of transitional memory phenotype (CD45RO(+)CD27(+)). Further, IL-10 receptor blocking antibody was able to protect the animals from GVHD. Since our results demonstrate a direct pathogenic role for IL-10, blockade of IL-10 signaling may provide a therapeutic option for GVHD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GVHD;; IL-10:; NSG mice; PBMCs;

Mesh:

Substances:

Year:  2014        PMID: 25463432      PMCID: PMC4310723          DOI: 10.1016/j.clim.2014.11.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  26 in total

1.  IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function.

Authors:  L Ding; E M Shevach
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

2.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Authors:  D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

3.  High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation.

Authors:  L Hempel; D Körholz; P Nussbaum; H Bönig; S Burdach; F Zintl
Journal:  Bone Marrow Transplant       Date:  1997-09       Impact factor: 5.483

4.  Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.

Authors:  Ming-Tseh Lin; Barry Storer; Paul J Martin; Li-Hui Tseng; Ted Gooley; Pei-Jer Chen; John A Hansen
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

5.  Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells.

Authors:  R M Weber-Nordt; R Henschler; E Schott; J Wehinger; D Behringer; R Mertelsmann; J Finke
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

6.  Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein.

Authors:  Y Levy; J C Brouet
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

7.  Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.

Authors:  B R Blazar; P A Taylor; S Smith; D A Vallera
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

8.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

Authors:  D F Fiorentino; A Zlotnik; P Vieira; T R Mosmann; M Howard; K W Moore; A O'Garra
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

9.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

Authors:  R de Waal Malefyt; J Haanen; H Spits; M G Roncarolo; A te Velde; C Figdor; K Johnson; R Kastelein; H Yssel; J E de Vries
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

10.  Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease.

Authors:  B R Blazar; P A Taylor; A Panoskaltsis-Mortari; S K Narula; S R Smith; M G Roncarolo; D A Vallera
Journal:  Transplantation       Date:  1998-11-15       Impact factor: 4.939

View more
  8 in total

Review 1.  Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases.

Authors:  Iurii Koboziev; Yava Jones-Hall; John F Valentine; Cynthia Reinoso Webb; Kathryn L Furr; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

2.  The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.

Authors:  N J Geraghty; L Belfiore; D Ly; S R Adhikary; S J Fuller; W Varikatt; M L Sanderson-Smith; V Sluyter; S I Alexander; R Sluyter; D Watson
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

3.  Cutting Edge: Inhibition of Glycogen Synthase Kinase 3 Activity Induces the Generation and Enhanced Suppressive Function of Human IL-10+ FOXP3+-Induced Regulatory T Cells.

Authors:  Hao Cheng; Lingbiao Wang; Biaolong Yang; Dan Li; Xiaoxia Wang; Xinnan Liu; Na Tian; Qianru Huang; Ru Feng; Zhengting Wang; Rui Liang; Sheng-Ming Dai; Ling Lv; Ji Wu; Yuan-Sheng Zang; Bin Li
Journal:  J Immunol       Date:  2020-08-19       Impact factor: 5.422

4.  Combination of IL-10 and IL-2 induces oligoclonal human CD4 T cell expansion during xenogeneic and allogeneic GVHD in humanized mice.

Authors:  Sojan Abraham; Hua Guo; Jang-Gi Choi; Chunting Ye; Midhun Ben Thomas; Nora Ortega; Alok Dwivedi; N Manjunath; Guohua Yi; Premlata Shankar
Journal:  Heliyon       Date:  2017-04-04

Review 5.  Insights into mechanisms of graft-versus-host disease through humanised mouse models.

Authors:  Amal Elhage; Chloe Sligar; Debbie Watson; Ronald Sluyter; Peter Cuthbertson
Journal:  Biosci Rep       Date:  2022-09-30       Impact factor: 3.976

6.  Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.

Authors:  Michael A Brehm; Laurie L Kenney; Michael V Wiles; Benjamin E Low; Roland M Tisch; Lisa Burzenski; Christian Mueller; Dale L Greiner; Leonard D Shultz
Journal:  FASEB J       Date:  2018-11-01       Impact factor: 5.834

7.  Acute Renal Graft-Versus-Host Disease in a Murine Model of Allogeneic Bone Marrow Transplantation.

Authors:  Peter M Schmid; Abdellatif Bouazzaoui; Karin Schmid; Christoph Birner; Christian Schach; Lars S Maier; Ernst Holler; Dierk H Endemann
Journal:  Cell Transplant       Date:  2017-08       Impact factor: 4.064

8.  Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation.

Authors:  Xiuhua Su; Qianqian Wang; Wei Guo; Xiaolei Pei; Qing Niu; Maolan Liu; Yuanyuan Liu; Song Chen; Sizhou Feng; Yi He; Donglin Yang; Rongli Zhang; Qiaoling Ma; Weihua Zhai; Aiming Pang; Jialin Wei; Yong Huang; Yuechen Luo; Mingzhe Han; Xiaoming Feng; Erlie Jiang
Journal:  Cell Mol Immunol       Date:  2019-10-29       Impact factor: 11.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.